Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - October 2011

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Adrenaline tartrate pre-filled pens (Jext®) have been accepted for the emergency treatment of severe acute allergic reactions. It is noted that this product has a longer shelf life compared to existing products.

Bromfenac eye drops (Yellox®) have been rejected for the treatment of postoperative ocular inflammation following cataract extraction in adults. The manufacturer failed to make a submission.

Fluorouracil and salicylic acid solution (Actikerall®) has been accepted for the topical treatment of grade I or II hyperkeratotic actinic keratosis in immunocompetent adult patients.

Olmesartan / amlodipine / hydrochlorothiazide tablets (Sevikar HCT®) has been accepted as a substitution therapy in adult patients whose blood pressure is adequately controlled on these three agents in different formulations.

Quetiapine modified release tablets (Seroquel XL®) have been rejected as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD). The manufacturer failed to make a submission.

Rosuvastatin tablets (Crestor®) have been rejected for the prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event. The manufacturer failed to present a sufficiently robust economic analysis to gain acceptance.

Vardenafil orodispersible tablets (Levitra®) have been accepted for restricted use in the treatment of erectile dysfunction (ED) in adult men in whom an orodispersible tablet is an appropriate formulation.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - October 2011' on Email Share 'SMC Update - October 2011' on Delicious Share 'SMC Update - October 2011' on Digg Share 'SMC Update - October 2011' on Facebook Share 'SMC Update - October 2011' on reddit Share 'SMC Update - October 2011' on Twitter

Generic olanzapine launched

Generic manufacturer Actavis has launched a generic version of olanzapine. The product has been launched as both conventional film coated tablets and as orodispersible tablets and is priced competitively compared to the pioneer brand Zyprexa®.

The potential cost savings will only be realised once the Drug Tariff prices are updated.

Reported prices are as follows:

  • 28 x 2.5mg tablets - £6.56
  • 28 x 5mg tablets - £13.11
  • 56 x 7.5mg tablets - £39.33
  • 28 x 10mg tablets - £26.22
  • 28 x 15mg tablets - £35.75
  • 28 x 20mg tablets - £47.67
  • 28 x 5mg orodispersible tablets - £14.42
  • 28 x 10mg orodispersible tablets - £26.22
  • 28 x 15mg orodispersible tablets - £39.33
  • 28 x 20mg orodispersible tablets - £52.44

These prices represent a 70% cost saving against the current prices for the pioneer brand.

Action: Clinicians should ensure prescriptions are issued generically to benefit from the cost savings made possible by this product launch.

Share 'Generic olanzapine launched' on Email Share 'Generic olanzapine launched' on Delicious Share 'Generic olanzapine launched' on Digg Share 'Generic olanzapine launched' on Facebook Share 'Generic olanzapine launched' on reddit Share 'Generic olanzapine launched' on Twitter

Newer Posts »

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer